Further evaluation of the convolutional neural network model as a potential biomarker of response to breast cancer chemoprevention will require use of large, prospectively obtained mammographic datasets among high-risk women who receive selective estrogen receptor modulators or aromatase inhibitors, as well as nonhormonal chemopreventive agents. The gene discussed is CYP19A1; the disease is breast carcinoma.